ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2017
Towards the Manufacture of Megakaryocytes and Platelets for Clinical Application.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Efficient chemical reprogramming of human T cells into functional megakaryocytes and platelets.Science advances · 2026Article
- Generation and single-cell characterization of functional megakaryocytes derived from umbilical cord blood.Stem cell research & therapy · 2026Article
- Developing a Multichannel Bioreactor with a Collagen Scaffold, ECM, and Cryoprecipitate to Significantly Produce Platelets from Umbilical Cord Blood Stem Cells.International journal of hematology-oncology and stem cell research · 2023Article
- Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention.Journal of clinical medicine · 2023Review
- Role of MicroRNA-326 and its Target Genes Bcl-xL and Bak as Potential Markers in Platelet Storage Lesion in Blood Banks.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2022Article
- Large-scale generation of megakaryocytes from human embryonic stem cells using transgene-free and stepwise defined suspension culture conditions.Cell proliferation · 2021Article
- Platelet production using adipose-derived mesenchymal stem cells: Mechanistic studies and clinical application.Journal of thrombosis and haemostasis : JTH · 2021Review
- Generation of HLA Universal Megakaryocytes and Platelets by Genetic Engineering.Frontiers in immunology · 2021Review
- Developments in the production of platelets from stem cells (Review).Molecular medicine reports · 2021Review
- [Cultured platelets].Bulletin de l'Academie nationale de medecine · 2020Review
- Functional properties of human platelets derived in vitro from CD34Scientific reports · 2020Article
- Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34Stem cells translational medicine · 2019Article
- Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors.Scientific reports · 2018Article
- On the Way toFrontiers in medicine · 2018Review
- Current status of blood 'pharming': megakaryoctye transfusions as a source of platelets.Current opinion in hematology · 2017Review
- A future without human leukocyte antigens?Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelet transfusions are used in standard clinical practice to prevent hemorrhage in patients suffering from thrombocytopenia or platelet dysfunctions. Recently, a constant rise on the demand of platelets for transfusion has been registered. This may be associated with several factors including demographic changes, population aging as well as incidence and prevalence of hematological diseases. In addition, platelet-regenerative properties have been started to be exploited in different areas such as tissue remodeling and anti-cancer therapies. These new applications are also expected to increase the future demand on platelets. Thus, in vitro generated platelets may constitute a highly desirable alternative to meet the rising demand on platelets. Several factors have been considered in the road trip of producing in vitro megakaryocytes and platelets for clinical application. From selection of the cell source, differentiation protocols and culture conditions to the design of optimal bioreactors, several strategies have been proposed to maximize production yields while preserving functionality. This review summarizes new advances in megakaryocyte and platelet differentiation and their production upscaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.